SynthesisWorld journal of surgical oncology2026
Reduced folate carrier 1 G80A polymorphism is correlated with elevated methotrexate-induced toxicity in pediatric acute lymphoblastic leukemia patients: a systemic meta-analysis.
Synthesis in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReduced folate carrier 1 (RFC1) is an important solute carrier transporter crucial for the uptake and transport of methotrexate (MTX). This meta-analysis aimed to systemically analyze the relationship between the RFC1 G80A polymorphism and MTX-induced toxicity in pediatric acute lymphoblastic leukemia (ALL) patients.
methodsA systematic search for studies reporting the correlation between the RFC1 G80A polymorphism and MTX-induced toxicity in pediatric ALL patients was performed via the Web of Science, EMBASE, PubMed, Wan Fang, CNKI, and VIP databases until June 16, 2025, followed by pooled analysis. The Newcastle‒Ottawa scale, Egger’s test, and leave‒one-out sensitivity analysis were performed to assess the study quality, publication bias and stability of the pooled results.
resultsThirteen eligible studies were included in this meta-analysis, with 2, 5, and 6 studies having Newcastle‒Ottawa Scale scores of 7 points, 8 points, and 9 points, respectively, indicating good study quality. The pooled prevalence of the RFC1 80 AA genotype was 28.29% (95% CI: 23.44%-33.15%) in pediatric ALL patients. The risks of overall toxicity (OR = 4.68, 95% CI: 1.96–11.15), myelosuppression (OR = 1.85, 95% CI: 1.30–2.65), hepatotoxicity (OR = 2.44, 95% CI: 1.14–5.21), and gastrointestinal toxicity (OR = 1.61, 95% CI: 1.03–2.52) were greater in pediatric ALL patients with the RFC1 80 AA genotype than in those with the RFC1 80 GG + GA genotype who underwent MTX treatment. However, neurotoxicity risk (OR = 0.98, 95% CI: 0.40–2.41) and mucositis risk (OR = 1.24, 95% CI: 0.81–1.89) were not different between the two groups. No publication bias existed, while some of the pooled results were not stable according to the sensitivity analysis.
conclusionThe RFC1 G80A polymorphism is closely correlated with elevated MTX-induced toxicity in pediatric ALL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.